La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato.

Translated title of the contribution: Surgical therapy of locally advanced non-small cell lung carcinoma

M. Martelli, G. Cardillo, M. Lopergolo, F. Facciolo

Research output: Contribution to journalArticle

Abstract

Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).

Original languageItalian
Pages (from-to)30-33
Number of pages4
JournalChirurgia Italiana
Volume47
Issue number3
Publication statusPublished - 1995

Fingerprint

Non-Small Cell Lung Carcinoma
Neoadjuvant Therapy
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Surgery

Cite this

La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato. / Martelli, M.; Cardillo, G.; Lopergolo, M.; Facciolo, F.

In: Chirurgia Italiana, Vol. 47, No. 3, 1995, p. 30-33.

Research output: Contribution to journalArticle

Martelli, M. ; Cardillo, G. ; Lopergolo, M. ; Facciolo, F. / La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato. In: Chirurgia Italiana. 1995 ; Vol. 47, No. 3. pp. 30-33.
@article{061e4f4f64ad47768bfd0859d061a261,
title = "La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato.",
abstract = "Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8{\%} and 40{\%} at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).",
author = "M. Martelli and G. Cardillo and M. Lopergolo and F. Facciolo",
year = "1995",
language = "Italian",
volume = "47",
pages = "30--33",
journal = "Chirurgia Italiana",
issn = "0009-4773",
publisher = "Bi & Gi Editori",
number = "3",

}

TY - JOUR

T1 - La terapia chirurgica del carcinoma del polmone non-microcitoma localmente avanzato.

AU - Martelli, M.

AU - Cardillo, G.

AU - Lopergolo, M.

AU - Facciolo, F.

PY - 1995

Y1 - 1995

N2 - Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).

AB - Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).

UR - http://www.scopus.com/inward/record.url?scp=0029434575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029434575&partnerID=8YFLogxK

M3 - Articolo

C2 - 8964096

AN - SCOPUS:0029434575

VL - 47

SP - 30

EP - 33

JO - Chirurgia Italiana

JF - Chirurgia Italiana

SN - 0009-4773

IS - 3

ER -